Effects of proteosome inhibition following moderate traumatic brain injury in the rat

Linda Daniels, Nancy E. Stagliano, Karell Curbelo, W. Dalton Dietrich, Helen Bramlett

Research output: Contribution to journalArticle

Abstract

Objectives: Proteasome inhibition following ischemia has previously been shown to be therapeutically beneficial in experimental models. The efficacy of this treatment strategy may be further tested clinically in a phase II clinical trial. Proteasome inhibition may be neuroprotective via an anti-inflammatory mechanism. Many of the neuropathological consequences of traumatic brain injury (TBI) parallel those of ischemic injury, but to our knowledge proteasome inhibition has not been evaluated in a clinically relevant TBI model. The purpose of this study was to evaluate the neuroprotective effects of proteasome inhibition following traumatic brain injury in the rat. Methodology: The acute effects of VELCADE®, a potent reversible proteasome inhibitor, were evaluated in 20 rats that underwent moderate fluid percussion (FP) brain injury. A single, bolus injection was administered 30 minutes after FP injury and the animals were sacrificed three days later for histopathological analysis. Contusion volume, neuronal survival (NeuN), and axonal damage (β-APP) were quantitatively assessed to evaluate the neuroprotective effects of this treatment strategy. Results: A neuroprotective trend in the VELCADE® group was found, with an increased number of NeuN positive cortical neurons surviving and a decreased number of β-APP immunoreactive axons compared to vehicle treated animals. However, no significant differences between the groups were found. Conclusion: The present findings did not show a significant effect of VELCADE® treatment using the present TBI model and outcome measures. However, alterations in the experimental design including different injury severities and treatment protocols may result in the detection of a more robust effect. The potential of proteasome inhibition as a treatment for secondary injury following TBI should be further assessed.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalInternational Journal of Neuroprotection and Neuroregeneration
Volume3
Issue number1
StatePublished - Oct 1 2006

Fingerprint

Proteasome Endopeptidase Complex
Percussion
Wounds and Injuries
Neuroprotective Agents
Phase II Clinical Trials
Proteasome Inhibitors
Contusions
Clinical Protocols
Brain Injuries
Axons
Anti-Inflammatory Agents
Research Design
Theoretical Models
Therapeutics
Ischemia
Outcome Assessment (Health Care)
Traumatic Brain Injury
Neurons
Injections

Keywords

  • MLN-519
  • Proteasome inhibition
  • PS-519
  • Traumatic brain injury
  • VELCADE®

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology

Cite this

Effects of proteosome inhibition following moderate traumatic brain injury in the rat. / Daniels, Linda; Stagliano, Nancy E.; Curbelo, Karell; Dalton Dietrich, W.; Bramlett, Helen.

In: International Journal of Neuroprotection and Neuroregeneration, Vol. 3, No. 1, 01.10.2006, p. 38-45.

Research output: Contribution to journalArticle

@article{ec9fa2239efd45a5afe73577c0c10e84,
title = "Effects of proteosome inhibition following moderate traumatic brain injury in the rat",
abstract = "Objectives: Proteasome inhibition following ischemia has previously been shown to be therapeutically beneficial in experimental models. The efficacy of this treatment strategy may be further tested clinically in a phase II clinical trial. Proteasome inhibition may be neuroprotective via an anti-inflammatory mechanism. Many of the neuropathological consequences of traumatic brain injury (TBI) parallel those of ischemic injury, but to our knowledge proteasome inhibition has not been evaluated in a clinically relevant TBI model. The purpose of this study was to evaluate the neuroprotective effects of proteasome inhibition following traumatic brain injury in the rat. Methodology: The acute effects of VELCADE{\circledR}, a potent reversible proteasome inhibitor, were evaluated in 20 rats that underwent moderate fluid percussion (FP) brain injury. A single, bolus injection was administered 30 minutes after FP injury and the animals were sacrificed three days later for histopathological analysis. Contusion volume, neuronal survival (NeuN), and axonal damage (β-APP) were quantitatively assessed to evaluate the neuroprotective effects of this treatment strategy. Results: A neuroprotective trend in the VELCADE{\circledR} group was found, with an increased number of NeuN positive cortical neurons surviving and a decreased number of β-APP immunoreactive axons compared to vehicle treated animals. However, no significant differences between the groups were found. Conclusion: The present findings did not show a significant effect of VELCADE{\circledR} treatment using the present TBI model and outcome measures. However, alterations in the experimental design including different injury severities and treatment protocols may result in the detection of a more robust effect. The potential of proteasome inhibition as a treatment for secondary injury following TBI should be further assessed.",
keywords = "MLN-519, Proteasome inhibition, PS-519, Traumatic brain injury, VELCADE{\circledR}",
author = "Linda Daniels and Stagliano, {Nancy E.} and Karell Curbelo and {Dalton Dietrich}, W. and Helen Bramlett",
year = "2006",
month = "10",
day = "1",
language = "English",
volume = "3",
pages = "38--45",
journal = "International Journal of Neuroprotection and Neuroregeneration",
issn = "1745-1183",
publisher = "RPA Publishers.",
number = "1",

}

TY - JOUR

T1 - Effects of proteosome inhibition following moderate traumatic brain injury in the rat

AU - Daniels, Linda

AU - Stagliano, Nancy E.

AU - Curbelo, Karell

AU - Dalton Dietrich, W.

AU - Bramlett, Helen

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Objectives: Proteasome inhibition following ischemia has previously been shown to be therapeutically beneficial in experimental models. The efficacy of this treatment strategy may be further tested clinically in a phase II clinical trial. Proteasome inhibition may be neuroprotective via an anti-inflammatory mechanism. Many of the neuropathological consequences of traumatic brain injury (TBI) parallel those of ischemic injury, but to our knowledge proteasome inhibition has not been evaluated in a clinically relevant TBI model. The purpose of this study was to evaluate the neuroprotective effects of proteasome inhibition following traumatic brain injury in the rat. Methodology: The acute effects of VELCADE®, a potent reversible proteasome inhibitor, were evaluated in 20 rats that underwent moderate fluid percussion (FP) brain injury. A single, bolus injection was administered 30 minutes after FP injury and the animals were sacrificed three days later for histopathological analysis. Contusion volume, neuronal survival (NeuN), and axonal damage (β-APP) were quantitatively assessed to evaluate the neuroprotective effects of this treatment strategy. Results: A neuroprotective trend in the VELCADE® group was found, with an increased number of NeuN positive cortical neurons surviving and a decreased number of β-APP immunoreactive axons compared to vehicle treated animals. However, no significant differences between the groups were found. Conclusion: The present findings did not show a significant effect of VELCADE® treatment using the present TBI model and outcome measures. However, alterations in the experimental design including different injury severities and treatment protocols may result in the detection of a more robust effect. The potential of proteasome inhibition as a treatment for secondary injury following TBI should be further assessed.

AB - Objectives: Proteasome inhibition following ischemia has previously been shown to be therapeutically beneficial in experimental models. The efficacy of this treatment strategy may be further tested clinically in a phase II clinical trial. Proteasome inhibition may be neuroprotective via an anti-inflammatory mechanism. Many of the neuropathological consequences of traumatic brain injury (TBI) parallel those of ischemic injury, but to our knowledge proteasome inhibition has not been evaluated in a clinically relevant TBI model. The purpose of this study was to evaluate the neuroprotective effects of proteasome inhibition following traumatic brain injury in the rat. Methodology: The acute effects of VELCADE®, a potent reversible proteasome inhibitor, were evaluated in 20 rats that underwent moderate fluid percussion (FP) brain injury. A single, bolus injection was administered 30 minutes after FP injury and the animals were sacrificed three days later for histopathological analysis. Contusion volume, neuronal survival (NeuN), and axonal damage (β-APP) were quantitatively assessed to evaluate the neuroprotective effects of this treatment strategy. Results: A neuroprotective trend in the VELCADE® group was found, with an increased number of NeuN positive cortical neurons surviving and a decreased number of β-APP immunoreactive axons compared to vehicle treated animals. However, no significant differences between the groups were found. Conclusion: The present findings did not show a significant effect of VELCADE® treatment using the present TBI model and outcome measures. However, alterations in the experimental design including different injury severities and treatment protocols may result in the detection of a more robust effect. The potential of proteasome inhibition as a treatment for secondary injury following TBI should be further assessed.

KW - MLN-519

KW - Proteasome inhibition

KW - PS-519

KW - Traumatic brain injury

KW - VELCADE®

UR - http://www.scopus.com/inward/record.url?scp=34548489379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548489379&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 38

EP - 45

JO - International Journal of Neuroprotection and Neuroregeneration

JF - International Journal of Neuroprotection and Neuroregeneration

SN - 1745-1183

IS - 1

ER -